Trevi Therapeutics, Inc. Board of Directors

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

Ms. Jennifer L. Good

Ms. Jennifer L. Good

Co-Founder, CEO, President & Director

Ms. Lisa Delfini

Ms. Lisa Delfini

Chief Financial Officer

Katie McManus

Katie McManus

Communications Manager

Mr. Christopher Galletta

Mr. Christopher Galletta

Controller & Chief Accounting Officer

Mr. Farrell Simon Pharm.D.

Mr. Farrell Simon Pharm.D.

Chief Commercial Officer

Dr. Thomas R. Sciascia M.D.

Dr. Thomas R. Sciascia M.D.

Co-Founder & Chief Scientific Officer

Ms. Danine Summers

Ms. Danine Summers

Vice President of Medical Affairs

Dr. James V. Cassella Ph.D.

Dr. James V. Cassella Ph.D.

Chief Development Officer

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.